ASTRAZEN inverted head and shoulder pattern,
AstraZeneca Pharma India Limited financials summary for FY 2025:
Annual Revenue (Net): ₹1,713.29 crore (up from ₹1,295.53 crore in FY 2024)
Total Revenue: ₹1,756.92 crore
Profit Before Tax (PBT): ₹156.36 crore
Profit After Tax (PAT): ₹115.74 crore
Earnings Per Share (EPS): ₹46.30 (Basic and Diluted)
Major cost components include materials consumed (₹287.13 crore) and employee expenses (₹257.44 crore)
Finance cost is low, around ₹1.46 crore
The company has shown consistent profit growth over recent years with a 5-year CAGR of around 19.4%
Equity dividend rate for FY 2025 was 1,600% of the face value
The company is almost debt-free and reported steady margin improvement
AstraZeneca Pharma India is financially healthy with substantial revenue growth, profitability, and strong earnings per share backed by pharmaceutical operations in India. The company continues to focus on specialty medicine and oncology segments, driving steady business expansion.
AstraZeneca Pharma India Limited financials summary for FY 2025:
Annual Revenue (Net): ₹1,713.29 crore (up from ₹1,295.53 crore in FY 2024)
Total Revenue: ₹1,756.92 crore
Profit Before Tax (PBT): ₹156.36 crore
Profit After Tax (PAT): ₹115.74 crore
Earnings Per Share (EPS): ₹46.30 (Basic and Diluted)
Major cost components include materials consumed (₹287.13 crore) and employee expenses (₹257.44 crore)
Finance cost is low, around ₹1.46 crore
The company has shown consistent profit growth over recent years with a 5-year CAGR of around 19.4%
Equity dividend rate for FY 2025 was 1,600% of the face value
The company is almost debt-free and reported steady margin improvement
AstraZeneca Pharma India is financially healthy with substantial revenue growth, profitability, and strong earnings per share backed by pharmaceutical operations in India. The company continues to focus on specialty medicine and oncology segments, driving steady business expansion.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.